Connect with us

Published

on

Jeff Bezos pops champagne after emerging from the New Shepard capsule after his spaceflight on July 20, 2021.
Blue Origin

All things must die, according to the poet Alfred Lord Tennyson, but that could be about to change.

A growing number of tech billionaires have decided they want to use their enormous wealth to try to help humans “cheat death.”

Amazon‘s Jeff Bezos, Alphabet‘s Larry Page, Oracle‘s Larry Ellison and Palantir’s Peter Thiel are just a few of the super-rich who have taken a keen interest in the fast-emerging field of longevity, according to interviews, books and media reports.

While breakthroughs are far from guaranteed, they hope that various medicines, therapies and other life science technologies will enable humans to live well beyond 100 years old and possibly to 200, 300, or even longer.

But are their efforts going to benefit humanity as a whole or just an elite few? It’s a tricky question that divides opinion.

The filter down effect

“Technologies that initially are only affordable to the rich typically become more widely available with time,” Stefan Schubert, a researcher at the London School of Economics and Political Science who specializes in “effective altruism,” told CNBC. Indeed, this is true of everything from air travel to smartphones and medicine.

Tech investor Jaan Tallinn, the co-founder of Skype, told CNBC that Silicon Valley’s quest to live forever will eventually benefit humanity as a whole.

“I think involuntary death is clearly morally bad, which makes the quest for longevity a morally noble thing to engage in,” Tallinn said. “Early adopters always tend to pay more and take larger risks than the ‘mass market,’ so if therapies start off on the expensive/risky side, that’s to be expected.”

Tallinn added that he thinks it’s “counterproductive” to require that a new service be available to everyone before anyone is allowed to use it, but he said he understands the instinct.

Sean O hEigeartaigh, co-director of Cambridge University’s Center for the Study of Existential Risk, told CNBC that many advances in longevity science could have broad benefits, adding that they could reduce the occurrence or severity of older age-related diseases including dementia and heart health.

“Extending max lifespan significantly in the near-term seems unlikely to me; but identifying and arresting aging-related factors that increase preponderance and severity of age-related conditions is more plausible,” Ó hÉigeartaigh said.

Some are concerned that the Earth’s finite resources could come under strain if people live longer, healthier lives.

However, by the time meaningful life extension advances are made, Ó hÉigeartaigh expects population numbers to be more stable in more parts of the world.

“I expect meaningful lifespan extension to be a century or more away, and by then I expect a parallel change in societal attitude towards euthanasia,” he said, adding that he thinks euthanasia will be more acceptable and more common in the coming years.

What about climate change?

While some believe that billionaires should be able to spend their money on what they see fit, not everyone thinks tech billionaires should be using their money to fund life extension research.

Jon Crowcroft, a computer science professor at Cambridge University, told CNBC they’d be better off pumping more of their billions into climate change mitigation technologies instead of longevity research.

“It’s a bit pointless living forever on a dying planet,” said Crowcroft.

But Tallinn told CNBC he finds the tech billionaire’s efforts to support longevity research “commendable.”

“I think it’s generally unfair to pit good causes against each other in a world where most resources are wasted on morally unimportant or even reprehensible things,” Tallinn said.

Billionaire’s chasing immortality

Bezos, the second richest man in the world behind Elon Musk, has invested some of his $199 billion into a new “rejuvenation” start-up called Altos Labs, according to a report from MIT Technology Review earlier this month.

The anti-ageing start-up, which is said to be pursuing biological reprogramming technology, is reportedly also backed by Russian-Israeli venture capitalist Yuri Milner, who made a fortune as an early investor in Facebook.

Elsewhere, Oracle founder Ellison has donated more than $370 million to research about aging and age-related diseases, according to The New Yorker.

Meanwhile, Google founders Sergey Brin and Larry Page helped launch Calico, a secretive venture that’s tracking mice from birth to death in the hope of finding markers for diseases like diabetes and Alzheimer’s, according to a report in The New Yorker. Calico is part of Alphabet, the holding company that also owns Google.

One of the biggest advocates for life extension among the tech billionaires is Thiel, who co-founded PayPal and Palantir and backed Donald Trump’s 2016 presidential campaign.

Peter Thiel, co-founder of PayPal Inc.
VCG | Getty Images

In 2006, he donated $3.5 million to support anti-ageing research through the non-profit Methuselah Mouse Prize foundation. “Rapid advances in biological science foretell of a treasure trove of discoveries this century, including dramatically improved health and longevity for all,” he said at the time. Thiel had upped his investment in Methuselah Mouse Prize foundation to $7 million by 2017, according to Time.

According to The New Yorker, Thiel and Bezos have both invested in San Francisco-based Unity Biotechnology, a company whose founder reportedly said he wants to “vaporize a third of human diseases in the developed world.”

Life extension stocks?

On the other side of the Atlantic, British billionaire Jim Mellon told CNBC last September that he was planning to take Juvenescence, his own life extension company, public in the next six to 12 months.

It’s yet to happen, but Juvenescence is continuing to invest in a wide range of anti-ageing therapies that it thinks have the potential to extend the human life.

One of those investments is Insilico Medicine, which aims to use artificial intelligence for drug discovery. Juvenescence has also backed AgeX Therapeutics, a California-headquartered firm trying to create stem cells that can regenerate ageing tissue, and LyGenesis, which wants to develop a technology that uses lymph nodes as bioreactors to regrow replacement organs.

Other billionaires, including Mike Cannon-Brookes, the co-founder of Australian software firm Atlassian, and NEX Group founder Michael Spencer, have invested in Juvenescence.

Continue Reading

Technology

Digital physical therapy provider Hinge Health files for IPO

Published

on

By

Digital physical therapy provider Hinge Health files for IPO

Hinge Health’s Enso product.

Courtesy: Hinge Health

Hinge Health, a provider of digital physical therapy services, filed to go public on Monday, the latest sign that the IPO market is starting to crack open.

Hinge Health uses software to help patients treat musculoskeletal injuries, chronic pain and carry out post-surgery rehabilitation remotely. The company’s revenue last year increased 33% to $390 million, according to its prospectus, and its net loss for the year narrowed to $11.9 million from $108.1 million a year earlier.

The IPO market has been quiet across the tech sector for the past three years, but within digital health it’s been almost completely silent, as companies have struggled to adapt to an environment of muted growth following the Covid-19 pandemic. No digital health companies held IPOs in 2023, according to a report from Rock Health, and last year the only notable offerings were Waystar, a health-care payment software vendor, and Tempus AI, a precision medicine company.

“We have many decades of work ahead,” Hinge Health CEO Daniel Perez said in the filing Monday. “We hope you join us on this journey.”

The company plans to trade on the New York Stock Exchange under the ticker symbol “HNGE.”

Perez and Gabriel Mecklenburg, Hinge Health’s chairman, co-founded the company in 2014 after experiencing personal struggles with physical rehabilitation, according to the company’s website.

Members of Hinge Health can access virtual exercise therapy and an electrical nerve stimulation device called Enso. The company claims its technology can help users improve their pain, reduce the need for surgery and cut down health-care costs.

The San Francisco-based company has raised more than $1 billion from investors including Tiger Global and Coatue Management, and it boasted a $6.2 billion valuation as of October 2021. The biggest outside shareholders are venture firms Insight Partners and Atomico, which own 19% and 15% of the stock, respectively, according to the filing.

Hinge Health’s dual class stock structure gives each share of Class B common stock 15 votes. Almost all of the Class B shares are owned by the founders and top investors.

Employees across more than 2,250 organizations, including Morgan Stanley, Target and General Motors, can access Hinge Health’s offerings. The company had more than 532,000 members as of Dec. 31, and more than 20 million people are eligible to enroll, the filing said.

Hinge Health declined to comment.

WATCH: The market is in a good environment for hedge funds

The market is in a good environment for hedge funds, says Citi's Mithra Warrier

Continue Reading

Technology

Fintech stocks plummet as Wall Street worries about consumer spending, credit

Published

on

By

Fintech stocks plummet as Wall Street worries about consumer spending, credit

People wait in line for t-shirts at a pop-up kiosk for the online brokerage Robinhood along Wall Street after the company went public with an IPO earlier in the day on July 29, 2021 in New York City.

Spencer Platt | Getty Images

It was a bad day for tech stocks, and a brutal one for fintech.

As the Nasdaq suffered its steepest decline since 2022, some of the biggest losers were companies that sit at the intersection of Wall Street and Silicon Valley.

Stock trading app Robinhood tumbled 20%, bitcoin holder Strategy fell 17% and crypto exchange Coinbase lost 18%. Much of the slide in those three stocks was tied to the drop in bitcoin, which fell almost 5%, continuing its downward trajectory. The price of the leading cryptocurrency is now down 19% in the past month, falling after a big-post election pop in late 2024.

Beyond the crypto trade, online lenders and payments companies also fell more than the broader market. Affirm, which popularized buy now, pay later loans, dropped 11%, as did SoFi, which offers personal loans and mortgages. Shopify, which provides payment technology to online retailers, fell more than 7%.

JPMorgan Chase fintech analysts on Monday highlighted declining consumer confidence as a potential challenge for companies that rely on consumer spending for growth. In late February, the Conference Board’s Consumer Confidence Index slipped to 98.3 for the month, down nearly 7%, the largest monthly drop since August 2021. Walmart recently reported a shift away from discretionary purchases, underscoring the potential trouble.

“Our universe has modestly outperformed the S&P 500 since the election, but sentiment has soured of late on declining consumer confidence and signs of slowing discretionary spend,” the JPMorgan analysts wrote.

The fintech selloff follows a strong rally in the fourth quarter, driven by Fed rate cut expectations and hopes for a more favorable regulatory environment under the Trump administration.

WATCH: PayPal CEO Alex Chriss on opportunities for consumers and small businesses

PayPal CEO Alex Chriss: Huge opportunity to deliver to consumers and help small business

Continue Reading

Technology

Oracle misses on earnings but touts data center growth from AI

Published

on

By

Oracle misses on earnings but touts data center growth from AI

Larry Ellison, chairman and co-founder of Oracle Corp., speaks during the Oracle OpenWorld 2017 conference in San Francisco on Oct. 1, 2017.

David Paul Morris | Bloomberg | Getty Images

Oracle issued quarterly results on Monday that trailed analysts’ estimates, but the company offered bullish comments on its cloud infrastructure segment.

Here is how Oracle did compared to LSEG consensus:

  • Earnings per share: $1.47 adjusted vs. $1.49 expected
  • Revenue: $14.13 billion vs. $14.39 billion expected

Revenue increased 6% from $13.3 billion in the same period last year. Net income rose 22% to $2.94 billion, or $1.02 a share, from $2.4 billion, or 85 cents a share, a year earlier. Revenue in Oracle’s cloud services business jumped 10% from a year earlier to $11.01 billion, accounting for 78% of total sales.

The company’s cloud infrastructure segment, which helps businesses move workloads out of their own data centers, has been booming due to demand for computing power that can support artificial intelligence projects. Oracle said revenue in its cloud infrastructure unit increased 49% from a year earlier to $2.7 billion.

“We are on schedule to double our data center capacity this calendar year,” Oracle Chair Larry Ellison said in a release. “Customer demand is at record levels.”

In January, President Donald Trump announced plans to invest billions of dollars in AI infrastructure in the U.S. in collaboration with Oracle, OpenAI and SoftBank. The first initiative of the joint venture, called Stargate, will be to construct data centers in Texas — an effort that is already underway, Ellison said during the announcement at the White House.

Oracle’s cloud and on-premises licenses business contributed $1.1 billion in revenue during the quarter, down 10% year over year.

Oracle also said it is increasing its quarterly dividend to 50 cents a share from 40 cents.

As of Monday’s close, the stock is down almost 11% year to date.

Oracle will hold its quarterly call with investors and will share its outlook at 5 p.m. ET.

Don’t miss these insights from CNBC PRO

Oracle misses on quarterly results, raises dividend by 25%

Continue Reading

Trending